Hammerman, Peter S.
Novartis Institutes for BioMedical Research, Inc.,
United States
2025 Rank: 156548
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Immunology
Rank in SubField 1: 5786 out of 355674 Researchers
Data For The Year: 2025
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 156548 | 172314 |
| Total Cites | 31847 | 34457 |
| H-index | 64 | 67 |
| Hm-index | 9 | 9 |
| Number of Single Authored Papers | 0 | 0 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 7 | 7 |
| Total Cites to Single+First Authored Papers | 3797 | 4262 |
| Number of Single+First+Last Authored Papers | 23 | 23 |
| Total Cites to Single+First+Last Authored Papers | 6374 | 6935 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 25594 | 27060 |
| Ratio of Total Citations to Distinct Citing Papers | 1.24 | 1.27 |
| Self-Citation Percentage |
7.57%
|
|
Hammerman, Peter S.
Novartis Institutes for BioMedical Research, Inc.,
United States
2024 Rank: 152288
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Immunology
Rank in SubField 1: 5732 out of 334837 Researchers
Data For The Year: 2024
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 152288 | 165213 |
| Total Cites | 29202 | 31686 |
| H-index | 61 | 66 |
| Hm-index | 9 | 9 |
| Number of Single Authored Papers | 0 | 0 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 7 | 7 |
| Total Cites to Single+First Authored Papers | 3621 | 4081 |
| Number of Single+First+Last Authored Papers | 23 | 23 |
| Total Cites to Single+First+Last Authored Papers | 5947 | 6498 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 23319 | 24697 |
| Ratio of Total Citations to Distinct Citing Papers | 1.25 | 1.28 |
| Self-Citation Percentage |
7.84%
|
|
Hammerman, Peter S.
Harvard Medical School,
United States
2023 Rank: 150404
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Immunology
Rank in SubField 1: 5716 out of 312644 Researchers
Data For The Year: 2023
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 150404 | 164007 |
| Total Cites | 26314 | 28681 |
| H-index | 58 | 62 |
| Hm-index | 8 | 8 |
| Number of Single Authored Papers | 0 | 0 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 7 | 7 |
| Total Cites to Single+First Authored Papers | 3438 | 3884 |
| Number of Single+First+Last Authored Papers | 23 | 23 |
| Total Cites to Single+First+Last Authored Papers | 5482 | 6017 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 20868 | 22177 |
| Ratio of Total Citations to Distinct Citing Papers | 1.26 | 1.29 |
| Self-Citation Percentage |
8.25%
|
|
Hammerman, Peter S.
Harvard Medical School,
United States
2022 Rank: 150886
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Immunology
Rank in SubField 1: 5719 out of 293195 Researchers
Data For The Year: 2022
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 150886 | 166292 |
| Total Cites | 22647 | 24799 |
| H-index | 52 | 54 |
| Hm-index | 8 | 8 |
| Number of Single Authored Papers | 0 | 0 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 7 | 7 |
| Total Cites to Single+First Authored Papers | 3171 | 3593 |
| Number of Single+First+Last Authored Papers | 23 | 23 |
| Total Cites to Single+First+Last Authored Papers | 4908 | 5414 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 17846 | 19016 |
| Ratio of Total Citations to Distinct Citing Papers | 1.27 | 1.30 |
| Self-Citation Percentage |
8.68%
|
|